Takeda Pharmaceutical Company Limited.
TAK.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company. It focuses on developing and marketing innovative medicines in several therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The co...Show More
Better Health for All
-10
Takeda's core business is devoted to health improvement, developing innovative medicines and vaccines for non-communicable diseases and neglected tropical diseases like dengue.
1
The company demonstrates exceptional support for healthcare workforce development, having trained over 110,000 health professionals and community health workers through CSR partnerships since 2016, and supported a decade-long program for healthcare worker training in African countries.
2
Takeda also contributes to healthcare education, reaching 4.1 million people with health education through CSR partnerships.
3
However, Takeda's health equity programs, with a $32 million commitment for new partnerships, represent approximately 0.11% of its 2023 pharmaceutical revenue, indicating minimal funding relative to its scale.
4
,
5
Furthermore, while Takeda publicly commits not to file for or enforce patents in least developed and low-income countries, it expresses reservations on compulsory licensing, which limits its overall patent flexibility for global health needs.
6
Fair Money & Economic Opportunity
0
Takeda Pharmaceutical Company Limited is a pharmaceutical company, and its core business does not involve lending, insuring, moving, or storing money for consumers. The 'Fair Money & Economic Opportunity' value is designed to assess financial institutions. Therefore, the company does not offer financial products or services that would be assessed by the KPIs under this value. While Article 1 mentions 'Financial Literacy Initiatives' with a projected reach of 25.2 million people in 92 countries by 2028
1
, this is a forward-looking statement and not evidence of current, achieved outcomes, as per the scoring rules. Consequently, no KPIs can be scored based on the provided evidence.
Fair Pay & Worker Respect
0
No specific, company-wide quantitative evidence was found across the provided articles to assess Takeda Pharmaceutical Company Limited against the defined KPIs for Fair Pay & Worker Respect. Information regarding employee engagement was specific to a subsidiary (Takeda Healthcare Philippines, Inc.) and could not be applied to the parent company. While articles mentioned labor disputes in subsidiaries (Philippines, Korea)
1
,
2
and historical total penalty amounts for employment-related offenses since 2000,
3
,
4
these did not provide the specific counts of *substantiated* labor law violations within the *past three years* required by the rubric. No data was available for living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, insecure contract share, or health insurance coverage for the global company.
Fair Trade & Ethical Sourcing
0
The provided articles indicate that Takeda has a Supplier Code of Conduct (SCoC) integrated into sourcing projects
1
and is a member of the Pharmaceutical Supply Chain Initiative (PSCI).
2
The company also has a Supplier Diversity, Equity, and Inclusion program, requiring prime suppliers to provide second-tier reporting
3
and aiming to include at least one small or diverse supplier in each request for proposal.
4
A Conflict Minerals Report for 2024 is available
5
, and corrective action plans (CAPs) are developed and tracked.
6
However, the articles do not provide specific quantitative data for any of the ethical sourcing KPIs, such as the percentage of fair-trade certified spend, audit frequency, number of forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage in contracts, share of spend on high-risk materials, or the percentage of procurement budget directed to diverse suppliers.
Honest & Fair Business
-30
Takeda has a Global Anti-Corruption Policy that prohibits the use of third-party intermediaries for prohibited activities.
1
This policy is supported by third-party intermediary assessments, regular audits, monitoring of high-risk transactions, root cause analysis, and remediation plans.
2
The company also maintains a Corporate Ethics & Compliance program, a Code of Conduct, and a Compliance Hotline/Helpline.
3
For whistleblowers, Takeda provides a hotline (1-888-TAKEDA-0), an online reporting system (EthicsPoint), and an Ethics Line available 24/7, alongside a policy of non-retaliation for good-faith concerns.
4
However, there is no evidence of independent investigation processes for whistleblower reports. Takeda utilizes independent external auditors for EHS audits, conducts third-party audits of suppliers against its Supplier Code of Conduct (including human rights and labor standards), and uses EcoVadis for supplier sustainability assessments.
5
A former employee was charged by the SEC with insider trading in 2008-2010
6
and settled for over $130,000,
7
but this was an individual action and not a company-level regulatory fine in the past three years.
Kind to Animals
-30
Takeda states that animal experiments are "essential" for drug research and development.
1
Its policy includes internal rules and committees with external members, such as the Institutional Animal Care and Use Committee (IACUC), to review and approve experiment plans.
2
The company is committed to the "3Rs" (Refining, Reducing, and Replacing) of animal research.
3
All R&D facilities that conduct animal research are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
4
Takeda Pharmaceuticals International has tested AxoSim’s microbrains to predict neurotoxicity of drugs.
5
The company is also a member of the IQ Consortium, which facilitates leadership groups including the 3Rs Translational and Predictive Sciences Leadership Group, aimed at sharing pharmaceutical innovation and quality best practices.
6
No War, No Weapons
0
Takeda Pharmaceutical Company Limited operates as a pharmaceutical company, focusing on medicines, research, and healthcare initiatives.
1
The provided articles consistently describe its business activities as entirely within the pharmaceutical value chain, with no mention of involvement in arms manufacturing, military contracts, or defense-related operations. Therefore, the company has no revenue from arms or defense contracts, no defense assets to divest, no exposure to controversial weapons, and no need for ethical red lines or compliance rates related to weapons, as these activities are not part of its core business model.
Planet-Friendly Business
-30
Takeda's net-zero GHG emission goals for operations by 2035 and for the entire value chain by 2040 were validated by the Science Based Targets initiative (SBTi) in 2024, aligning with a 1.5°C temperature reduction pathway.
1
An interim target aims to reduce Scope 1 and 2 GHG emissions by 40% by 2025.
2
In 2022, the company achieved an 80% waste diversion rate from landfill, with a target to reach over 90% by FY2025
3
and zero waste-to-landfill at all major locations by 2030.
4
Respect for Cultures & Communities
20
Takeda has no reported cultural appropriation incidents. Its medicinal botanical garden, an operational area located near the ancient Kyoto temple of Manshuin, was designated as a registered museum on January 31, 2024, and no incidents disrupting cultural or heritage sites have been reported.
1
Safe & Smart Tech
0
Takeda holds multiple security and privacy certifications, including PCI, HIPAA, SOC 2, GDPR, ISO 27001, FedRamp, and CSA Star Level 1.
1
The company states that data is stored on computer systems with encryption.
2
Takeda indicates that users can decline data sharing, and data is retained only for the minimum period necessary.
3
The company also states compliance with various laws, including GDPR and HIPAA.
4
Zero Waste & Sustainable Products
-20
Takeda achieved an 80% waste diversion rate from landfill as of 2022.
1
The company has set company-wide waste reduction targets, including achieving zero waste-to-landfill for all major locations by FY2030
2
and a 90%+ waste diversion rate by FY2025.
3
Takeda has implemented over 10 waste reduction initiatives, such as a ton-scale pilot for closed-loop recycling of single-use trays,
4
a global Climate Action Program at Sites,
5
and investments of $10 million and $4 million in biomedical plastic waste processing facilities.
6
The Jaguariúna, Brazil facility achieved 100% zero-waste-to-landfill status since 2020, encompassing hazardous waste, and implemented a paperless project eliminating 40,000 pages annually.
7
Takeda's "Sustainability by Design" program applies circular economy principles, conducting life cycle assessments on three compounds with concrete proposals expected by the end of 2022.
8